2024
Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research 2024, 272: 1-11. PMID: 39142215, DOI: 10.1016/j.schres.2024.07.035.Peer-Reviewed Original ResearchClinical Global Impression ScaleSchizophrenia spectrum disordersPositive and Negative Syndrome ScaleBaseline PANSS total scoreAntipsychotic polypharmacyPANSS total scoreTotal scorePositive symptomsPsychotic patientsPositive and Negative Syndrome Scale positive symptom subscaleNegative symptom subscale scoreSubgroup of psychotic patientsBaseline positive symptomsExtrapyramidal side effectsNegative Syndrome ScalePositive symptom subscaleSecond-generation antipsychoticsGlobal Impression ScaleModerators of efficacySeverely psychotic patientsStudy-level moderatorsStudy discontinuationSymptom subscale scoresAntipsychotic monotherapySyndrome Scale
2015
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72: 1037-1044. PMID: 26351969, PMCID: PMC4811029, DOI: 10.1001/jamapsychiatry.2015.1472.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderSymptom-onset dosingSerotonin reuptake inhibitorsDays of mensesSSRI withdrawalSymptom onsetSymptomatic daysMenstrual cycleClinical trialsDysphoric disorderOutcome measuresScale scoreSRI treatmentTreatment of PMDDClinical Global Impression ScaleAbrupt treatment cessationDepressive Symptomatology-ClinicianTotal DRSP scoresSecondary outcome measuresPrimary outcome measureGlobal Impression ScaleIDS-C scoresUniversity Medical CenterSertraline hydrochlorideBeginning of menses
2005
Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample
Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample. Biological Psychiatry 2005, 58: 97-104. PMID: 15936729, DOI: 10.1016/j.biopsych.2005.03.041.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal repetitive transcranial magnetic stimulationClinical Global Impression ScaleGlobal Impression ScaleRight-handed patientsMotor thresholdImpression ScaleRTMS effectsNew patientsNeurocognitive impairmentHallucination frequencySchizoaffective disorderPatient samplesSignificant distressPatientsChange scoresHallucinationsPreliminary reportStimulationNeurobiological factorsIntervention